

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

PODESTA GROUP, INC

2. Address:

1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001

3. Principal place of business (if different from line 2):

4. Contact Name: KIMBERLEY FRITTS

Telephone: 2023931010

E-mail (optional): LOBBYING@PODESTA.COM

Senate ID #: 31680-238

House ID #:

7. Client Name: ☐ Self

GENZYME

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 80,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Sec. 751 drug safety; issues within the bill: drug safety, Critical Path, and follow-on biologics Senate version of bill: Title IV - Sec. 742 FDA conflict on interest language, issues, within the bill Authorized Generics, Citizen's Petition, FTC, Personalized Medicine, follow-on biologics, Critical Path H.R. 5672 - FY2007 Science, State, Justice, and Commerce Appropriations bill or Commerce, State, and Justice Appropriations bill--"Patents/PTO" H.R. 5441 - FY 2007 Homeland Security Appropriations bill -- House version of bill - Section 532 "Customs Drug Importation provision" Senate version of bill - Sec. 540 - Customs Drug Importation provision H.R. 5647 - FY 2007 Labor, Health, and Human Services and Education and Related Agencies Appropriations bill House Committee Reported bill - Title II - drug, pricing, drug safety H.R. 5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007 House version of bill, Title VI - Sec. 742: Conflict of Interest; Sec 749 Drug Importation;

17. House(s) of Congress and Federal agencies contacted:
HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: EDGAR-GOODING, REBECCA

Covered Official Position (if applicable): N/A

Name: KAUDERS, ANDREW

Covered Official Position (if applicable): SR ADV, SEN. MENENDEZ; ED, HOUSE DEM CAUCUS

Name: MORRA, ELIZABETH

Covered Official Position (if applicable): N/A

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: SICILIANO, JEN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: PODESTA GROUP, INC Client Name: GENZYME

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R.2795, Patent Act of 2005 Process Patents Patent Reform S 3818, Patent Act of 2006

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: PODESTA, ANTHONY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.4241, Deficit Reduction Act of 2005 S.1932, Deficit Reduction Omnibus Reconciliation Act of 2005 Medicare Implementation; Flow Cytometry; Medicaid; 340B Program; HOPPS 2007 Reimbursement HR 6111, Tax Relief and Health Care Act of 2006

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

Executive Office of the President (EOP)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: GERARD, RANDALL

Covered Official Position (if applicable): N/A

Name: NICHOLS, SETH

Covered Official Position (if applicable): N/A

Name: PODESTA, ANTHONY

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

FDA, drug approval, generics biologics, importation, clinical trial, drug and safety, PDUFA, conflict of interest HR 2090, Food and Drug Administration Improvement Act of 2005 HR 6257, Access to Life-Saving Medicine Act S 3807, Enhancing Drug Safety and Innovation Act of 2006 S 4016, Access to Life-Saving Medicine Act H.R.700, Pharmaceutical Market Access and Drug Safety Act of 2005, Importation S.109/H.R. 328, Pharmaceutical Market Access Act of 2005 S.334, Pharmaceutical Market and Drug Safety Act of 2005 S.930, Food and Drug Administration Safety Act of 2005

17. House(s) of Congress and Federal agencies contacted:

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: HAGEN, COURTNEY
Covered Official Position (if applicable): N/A
Name: NICHOLS, SETH
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: KIMBERLEY FRITTS, CEO -

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: EDGAR-GOODING, REBECCA

Name: SICILIANO, JEN

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 14, 2007

Printed Name and Title: -